Avid Bioservices

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Avid Bioservices Achieves Record Revenues, Faces Margin Challenges

Avid Bioservices achieved record revenues and strong bookings, but faced challenges with decreased gross margins and increased expenses. Moving into the viral vector space and with a strong late-phase project pipeline, the company sees opportunities for growth in the next 12 to 15 months.

Avid Bioservices reports Q2 earnings, focuses on expansion and innovation

Avid Bioservices showcased positive operational performance with increased utilization of the new mammalian line fleet and a record backlog. While facing challenges related to net loss and revenue recognition delays, the company remains focused on expansion and innovation, presenting opportunities for growth in the cell and gene therapy space and later-stage products.

Avid Bioservices reports robust Q3 earnings and targets pharma growth

Avid Bioservices delivered strong financial results in Q3 2023, showcasing revenue growth and operational efficiency.
While facing challenges in margins and expenses, the company's strategic focus on quality and growth presents opportunities for expansion.
With a solid cash position, record backlog, and targeted business development, Avid is poised for continued success in the market.

Avid Bioservices reports record revenues and backlog, eyes strategic growth

Avid Bioservices delivered a strong performance in Q4 2023, marked by record revenues and backlog, showcasing operational efficiency and market demand.
While facing challenges such as margin impact and resource allocation shifts, the company remains optimistic about its growth prospects and revenue stability.
Strategic opportunities lie in leveraging the strong backlog, cash flow, and planned CapEx to drive future growth and operational excellence.

Avid Bioservices reports revenue growth and expansion plans for 2024

Avid Bioservices' Q1 2024 performance reflects revenue growth and strategic investments in expanding capacity and capabilities.
While facing challenges in gross margins and profitability, the company's progress on the new facility signals future growth potential.
Opportunities lie in leveraging the completed facility to drive revenue, enhance market competitiveness, and address analyst concerns for improved performance.

Avid Bioservices reports record backlog and growth opportunities for 2024

Avid Bioservices showcased financial resilience with an improved cash position and strong backlog, despite facing revenue challenges. The company's focus on new services, customer diversity, and operational efficiency bodes well for future growth.

Avid Bioservices reports revenue growth and strategic expansions in Q3

Avid Bioservices reported strong revenue growth and backlog performance in Q3, while facing revenue decline and cost challenges compared to the previous year. Strategic expansions and operational refinements position the company for future opportunities in a competitive market landscape.

Avid Bioservices reports revenue growth and new projects, faces cost challenges

Avid Bioservices reported positive revenue growth and secured new project agreements, positioning the company for future expansion.
Despite challenges such as increased SG&A expenses and a net loss, Avid's focus on capacity utilization and new programs offers growth potential.
Addressing operational challenges and uncertainties while capitalizing on opportunities can drive Avid Bioservices towards improved financial performance.
The company's financial stability, strong backlog, and focus on profitability highlight a resilient business strategy amidst industry dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. It focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.

Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript

-- Appointed Nicholas Green as President and Chief Executive Officer --   -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million --

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments

Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion

Avid Bioservices Names Nicholas Green as President and Chief Executive Officer

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Avid Bioservices (CDMO) to Report a Decline in Earnings: What to Look Out for

Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances

Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing

Enphase Energy

These two businesses offer compelling growth potential, but one has yet to deliver on its promise and the other just became more complicated thanks to the coronavirus pandemic.

2 High-Risk, High-Reward Stocks to Add to Your Watch List

TUSTIN, Calif., April  13, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of two senior directors of business development with responsibility for driving CDMO business growth within North America, Europe and Asia.  Jason C. Brady, Ph.D. will serve as senior director of business development for the eastern region of North America, as well as Europe.  Sylvia Hinds has been named senior director of business development for the western region of North America in addition to the Asia Pacific region.

Avid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America, Europe and Asia

Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry

Avid Bioservices Receives Five 2020 CMO Leadership Awards

The drug manufacturer encountered an operational setback, which forced it to slash revenue guidance.

Here's Why Avid Bioservices Tumbled Today

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q3 2020 Results - Earnings Call Transcript

Avid Bioservices (CDMO) delivered earnings and revenue surprises of -100.00% and -19.14%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Reports Q3 Loss, Misses Revenue Estimates

Avid Bioservices (NASDAQ:CDMO) reported Q3 results. Quarterly Results • Earnings per share decreased 20% year over year to a loss of $0.06, which missed the estimate by $0.02.

Recap: Avid Bioservices Q3 Earnings

TUSTIN, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

Avid Bioservices  Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Will Avid Bioservices (CDMO) Report Negative Q3 Earnings? What You Should Know

Company Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience Company Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience

Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer

Endo International

IGM Biosciences Inc

Illumina

IVERIC bio Inc

Kodiak Sciences Inc

Mylan

Neovasc

Pacira Pharmaceuticals

Pfizer

X4 Pharmaceuticals Inc

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

11 Biotechs and Pharma Stocks Being Given Huge Upside Targets for 2020

Pacific Biosciences of California

These two small-cap stocks are risky, but not as risky as penny stocks. And buying a small stake in either company could actually pay off for patient investors.

About to Buy Penny Stocks ?  Look At These 2 Companies First

The drug manufacturing company reported operating results for its fiscal second quarter.

Here's Why Avid Bioservices Jumped as Much as 22.2% Today

Avid Bioservices, Inc. (CDMO) CEO Rick Hancock on Q2 2020 Results - Earnings Call Transcript

-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% --    -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed --

Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments

TUSTIN, Calif., Dec.  04, 2019  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

Avid Bioservices - Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Avid Bioservices (CDMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Senior Executive with More than 25 Years of Biopharmaceutical Industry Manufacturing Operations Experience Senior Executive with More than 25 Years of Biopharmaceutical Industry Manufacturing Operations Experience

Avid Bioservices Names Richard Richieri as Chief Operations Officer

Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories

News for Avid Bioservices Stock (CDMO)